The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market. Bayer won the EU agency's endorsement for Stivarga, a targeted drug for colorectal cancer, which is partnered with Onyx Pharmaceuticals ($ONXX). Raptor Pharmaceuticals garnered the EMA's blessing for marketing its therapy Procysbi for the most common form of a rare genetic disease called cystinosis. As usual, the European Commission will decide within months whether to take the advice of the EMA. Stivarga news | Procysbi news